<DOC>
	<DOCNO>NCT00588835</DOCNO>
	<brief_summary>The purpose study determine whether aprepitant use Cisplatin - Etoposide chemotherapeutic regimen .</brief_summary>
	<brief_title>Pharmacokinetic Study Addition Aprepitant Cisplatin - Etoposide Treatment Lung Cancer Patients</brief_title>
	<detailed_description>Aprepitant act initially moderate inhibitor CYP3A4 follow short period CYP3A4 induction . Etoposide substrate CYP3A4 may therefore suvject drug interaction aprepitant . CE classify highly emetogenic chemotherapeutic regimen use aprepitant may therefore consider clinically relevant drug interaction etoposide determine .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>18 75 year age able willing sign inform consent form indication treatment CE regimen subject expect receive least 2 cycle CE regimen able swallow capsule history sensitivity/idiosyncrasy aprepitant excipients condition might interfere drug absorption , distribution metabolism excretion . history current abuse drug , alcohol solvent inability understand nature extent trial procedure participation drug trial within 30 day prior first dose febrile illness within 3 day first dose concomitant use agent know interfere aprepitant pharmacokinetics abnormal liver renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>nausea vomit post chemotherapy</keyword>
</DOC>